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Muscle creatine kinase (MCK) is expressed at high levels only in skeletal and cardiac muscle tissues. Previous
in vitro transfection studies of skeletal muscle myoblasts and fibroblasts had identified two MCK enhancer
elements and one proximal promoter element, each of which exhibited expression only in differentiated skeletal
muscle. In this study, we have identified several regions of the mouse MCK gene that are responsible for
tissue-specific expression in transgenic mice. A fusion gene containing 3,300 nucleotides of MCK 5' sequence
exhibited chloramphenicol acetyltransferase activity levels that were more than 104-fold higher in skeletal
muscle than in other, nonmuscle tissues such as kidney, liver, and spleen. Expression in cardiac muscle was also
greater than in these nonmuscle tissues by 2 to 3 orders of magnitude. Progressive 5' deletions from nucleotide
-3300 resulted in reduced expression of the transgene, and one of these resulted in a preferential decrease in
expression in cardiac tissue relative to that in skeletal muscle. Of the two enhancer sequences analyzed, only
one directed high-level expression in both skeletal and cardiac muscle. The other enhancer activated expression
only in skeletal muscle. These data reveal a complex set of cis-acting sequences that have differential effects on
MCK expression in skeletal and cardiac muscle.
Terminal differentiation in skeletal muscle leads to the
activation of many muscle-specific genes. including those
encoding myosin heavy and light chains. a-actin, troponins I
and T, tropomyosin, acetylcholine receptor, and creatine
kinase (for a review, see reference 4). Some of these genes
are expressed in cardiac as well as skeletal muscle, and
expression varies significantly during development and mat-
uration of these tissues. A key step in understanding how
these differential patterns of expression are established and
modulated is identification of cis-acting regulatory se-
quences in the muscle-specific genes. Much attention has
been directed toward identifying such sequence elements by
using permanent skeletal myoblast cell lines (1, 2. 6, 8. 19.
20, 22, 26, 27, 31). However, relatively little is known about
the sequences that govern expression of these genes in
cardiac muscle (10, 24, 34, 36).
Muscle creatine kinase (MCK) is expressed at high levels
in both skeletal and cardiac muscle of adult animals (11, 21,
32, 40). Activation of MCK transcription during skeletal
myoblast differentiation has been shown (7, 19. 29, 30, 33).
and multiple cis-acting regulatory sequences have been
identified in the 5' flanking sequence and first intron of the
MCK gene (20, 39). The best-characterized element is a
207-base-pair (bp) muscle-specific enhancer located about
1,100 nucleotides (nt) 5' of the MCK transcription start site.
Another enhancer element is located within a 900-nt region
in the first intron. The proximal 776-nt 5' MCK sequence
also displays muscle cell type specificity in cultured cells,
but the absolute level of expression from this element is
quite low compared with expression when either enhancer is
present (20). A myocyte-specific binding activity. MEFI,
that interacts with both enhancers but not the proximal
element has been identified (5). Furthermore, the intact
MEFi site is required for the 5' enhancer to function in
MCK expression during skeletal myoblast differentiation in
culture.
* Corresponding author.
The ability of these MCK regulatory sequences to function
in cardiac muscle expression of the MCK gene has not been
studied in cell culture because of the lack of convenient
cardiac muscle cell lines. However, recent reports describ-
ing the function and tissue distribution of the myogenic
determination factors MyoDl and myogenin raise important
questions about the regulatory sequences in those muscle-
specific genes that are expressed in both skeletal and cardiac
muscle (9. 42). MyoDl and myogenin are found only in
skeletal muscle, not in cardiac muscle (9, 42); interestingly,
MyoDl has been shown to be identical or closely related to
the MEF1 MCK-binding activity (J. Buskin, A. B. Lassar,
R. L. Davis, H. Weintraub, and S. D. Hauschka, J. Cell
Biol. 107:98a, 1988; A. B. Lassar, J. N. Buskin, D. Lock-
shon, R. L. Davis, S. Apone, S. D. Hauschka, and H.
Weintraub, submitted for publication). Do the MCK regula-
tory sequences identified in skeletal muscle also function in
cardiac muscle? To study this question and the function of
MCK regulatory sequences in all tissues, we have con-
structed transgenic mice containing seven different MCK-
chloramphenicol acetyltransferase (CAT) fusion genes. Here
we report expression levels of these genes in skeletal and
cardiac muscle as well as in nonmuscle tissues of adult mice.
Evidence for regulatory elements with differential effects on
MCK expression in skeletal versus cardiac muscle is pre-
sented.
MATERIALS AND METHODS
DNA constructions. Construction of -3300MCK-CAT,
-1256MCK-CAT, -776MCCK-CAT, -723MCK-CAT.
-80MCK-CAT, and p118CAT has been described elsewhere
(20). -117MCK-CAT was constructed by blunt-end ligation
of the 117-bp SinaI fragment from MCK 5' flanking sequence
into XbaI-cut p118CAT. This resulted in an MCK-CAT
junction at nt +1 instead of at nt +7, as in all other
MCK-CAT fusion genes. E1-117MCK-CAT was con-
structed by blunt-end ligation of the SplI-BamHI enhancer-
containing fragment from - 1256MCK-CAT into the SalI site
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FIG. 1. Maps of MCK-CAT fusion genes. The CAT structural gene-simian virus 40 poly(A) cassette (14) was fused to MCK 5' regions at
nt +7 in all constructs except El-117MCK-CAT. in which the fusion was at nt +1. Symbols: _ enhancer fragment from nt -1256 to
-1049, referred to as El; , -900-bp Hi,idlll enhancer fragment from the first intron, referred to as E2; approximately 160 bp of
pUC118 from the polylinker Hinidlll to the NorI and Bgll sites in constructs E2-776MCK-CAT and E2-80MCK-CAT, respectively; *,
approximate assignment. In all constructs, the enhancers El and E2 are in their proper 5'-to-3' orientations except in E2-80MCK-CAT. in
which the E2 enhancer is in the opposite orientation.
of -117MCK-CAT. E2-776MCK-CAT and E2-80MCK-
CAT were made by ligation of the -900-bp HinidIII fragment
from the first intron of MCK into HinzdIII-cut -776MCK-
CAT and -80MCK-CAT, respectively.
Production of transgenic mice. DNA restriction fragments
containing the fusion genes were separated from plasmid
vector sequences by agarose (Bethesda Research Laborato-
ries, Inc.) gel electrophoresis. The DNA was purified from
the agarose by being dissolved in 8 M sodium perchlorate.
bound to GFC paper (Whatman, Inc.), and eluted in 1 mM
Tris hydrochloride (pH 7.5S-0.1 mM EDTA. The DNA was
diluted to a final concentration of 1.5 pLg/ml in 10 mM Tris
hydrochloride (pH 7.4)-0.1 mM EDTA.
DNA was injected into one of the pronuclei in F. hybrid
eggs (obtained by mating C57BL/6 x DBA/2 hybrid adults).
Injected eggs were maintained in M16 culture medium (18)
overnight in a humidified 37°C incubator (5% CO). Two-cell
embryos were reimplanted into the oviducts of pseudopreg-
nant foster mothers. Positive founder mice were identified
by DNA dot blots and, in most cases, outbred to generate
heterozygous lines. E2-80MCK-CAT founder mice were
sacrificed for analysis and not outbred.
Preparation and analysis of DNA. High-molecular-weight
tail DNA was isolated by incubating 1- to 2-cm tail pieces in
1.5 ml of 20 mM Tris hydrochloride (pH 7.5)-400 mM
NaCI-2 mM EDTA-0.S% sodium dodecyl sulfate-500 ,ug of
proteinase K for 8 h at 55°C. DNA was then phenol-
chloroform extracted, ethanol precipitated, and suspended
in 10 mM Tris hydrochloride (pH 7.5)-l mM EDTA. Initial
surveys for the presence of transgenes used DNA dot blots.
These were performed by denaturing the tail DNA for 2 min
at 100°C in 2 M NaCl-0.2 M NaOH and spotting onto
nitrocellulose filters. Filters were hybridized to a 32P-labeled
HiidIII-BaonHI fragment containing the CAT gene (14) at
42°C overnight in 50%Y formamide-450 mM NaCl-45 mM
sodium citrate (pH 7.0)-50 mM NaH2PO4 (pH 6.5)-0.1 mg of
herring sperm DNA per ml-10% dextran sulfate and then
washed three times for 30 min at 50°C in 0.5% sodium
dodecyl sulfate-10 mM Tris hydrochloride (pH 7.8)-5 mM
EDTA. DNA samples scoring positive for the presence of
CAT sequences in the dot screen were then analyzed by
standard DNA gel blots (38) to test for intact genes and to
determine the DNA copy number. Most mice containing the
transgene were outbred with (C57BL/6 x DBA/2)F1 mice.
E2-80MCK-CAT founder mice were sacrificed directly for
analysis.
Assay for CAT enzyme. Tissue extracts were prepared by
Dounce homogenization in 250 mM Tris hydrochloride (pH
7.8)-5 mM EDTA. Homogenates were microcentrifuged at
4°C for 10 min; the supernatant was then incubated at 68°C
for 10 min and microcentrifuged again at 4°C for 10 min, and
the final supernatant was stored at -20°C. Soluble protein
concentrations were determined by Bradford assays (3).
Tissue extracts were assayed for CAT activity by incubation
for 1 h at 37°C with [14C]chloramphenicol (0.2 p.Ci/p.l: 60
mCi/mmol; Dupont, NEN Research Products) and 1 mM
acetyl coenzyme A in 300 mM Tris hydrochloride (pH 7.8).
Chromatographic separation and quantitation were per-
formed as previously described (14) except that the scintil-
lant was Ecolite (Westchem). Each assay contained between
0.1 ng and 200 p,g of protein so that the fraction of chloram-
phenicol acetylated in the assay was linear with enzyme
activity. Total protein in the reaction mix was held constant
by using bovine serum albumin. Interference in CAT activity
assays has been noted in extracts from some tissues (25). In
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TABLE 1. CAT activity in tissues of adult
-3300MCK-CAT transgenic mice
CAT activity (mean ,uU/mg of protein t SD)
Tissue in given mouse line"
1 2 3 4
Skeletal muscleb 3 x 105 6 x 107 ± 3 x 107 9 X 107 2 x lOl
Cardiac muscle 1 x 104 8 x 105+ 5 x 105 1 x 106 1 x 106
Lung ' 6 x 104 6 x 104 2 x 105
Brain 1 x 102 6 x 104 4 x 104 3 x 104 1 X 105
Testis 30 2 x 104 1 X 104
Uterus 1 x 104 1 X 104
Blood 6 x 103
Kidney 3 1x104 1X104 2 x 103 3 x103
Liver 3 8 x 103 1 X 103 3 x 103
Spleen 3 x 103 8 x 102 6 x 103
" A unit of CAT activity is defined as the amount sufficient to acetylate 1
,umol of chloramphenicol per min (37). Data are from two to eight adult mice.
Standard deviations are given only for data averaged from tissues of eight
mice. See legend to Fig. 1 for description of the transgene -3300MCK-CAT.
Transgenic mouse line 1 contains 3 to 5 copies of the transgene -3300MCK-
CAT; lines 2, 3, and 4 contain 5 to 10 copies.
b Superficial gluteus muscle.
-, Not determined.
interference by mixing experiments. No interference was
detected in extracts from leg muscle, brain, lung, or testis.
Low-level interference was detected in extracts from spleen
(<140 p.U/mg of protein) and from kidney, liver, and heart
(<20 ,uU/mg of protein). This degree of interference had no
significant effect on the conclusions reported. Enzyme ac-
tivity was expressed in units as defined by Shaw and
Brodsky (37).
RESULTS
Production of transgenic mice containing MCK-CAT fusion
genes. Transgenic mice containing MCK 5' and intragenic
sequences fused to the protein-coding sequence of CAT
were generated. Structures of the seven MCK-CAT fusion
genes used are shown in Fig. 1. Four of these structures
represent a 5' deletion series containing 3,300, 1,256, 723,
and 80 nt of the MCK upstream sequences. The other three
constructs contain skeletal muscle-specific enhancers (de-
fined previously by their activity in cultured cells) juxta-
posed to various MCK 5' flanking sequences. All constructs
were introduced into the mouse germ line by microinjection
of MCK-CAT DNA that had been linearized and purified
from vector sequences (except for approximately 160 bp of
pUC118 on the 5' end of E2-776MCK-CAT and
E2-80MCK-CAT). Southern blots showed that the trans-
genes were primarily arranged in head-to-tail arrays. The
gene copy number in each line was estimated by comparing
transgene band intensities with the intensity of an endoge-
nous single-copy gene (J. E. Johnson, Ph.D. thesis, Univer-
sity of Washington, Seattle, 1988). Copy numbers range
TABLE 2. CAT activity in tissues of adult transgenic mice carrying various MCK-CAT fusion genes"
No. of CAT activity (mean ,uU/ml of protein ± SD) in6:Transgene Line Copy no. mietsd
TransgeneL.mice tested Kidney Cardiac muscle Skeletal muscle'
-3300MCK-CAT 1 3-5 2 3 1 x 104 3 x 105
2 5-10 8 1X104+1X104 8x105 5x1056x107±3x107
3 5-10 2 2 x 103 1 X 106 9 X 107
4 5-10 2 3 x 103 1 x 106 2 x 108
-1256MCK-CAT 5 2-5 2 60 2x103 3 x105
6 2-5 4 10 2x10 6 x 106
7 2-5 2 80 3 x 102 6 x 106
-723MCK-CAT 8 1-3 4 <2 <2 <2
9 5-10 4 <2 <2 20
10 10-15 3 <2 3 2 x 103
11 15-20 7 <2 3 3 x 103 -+- 3 x 103
12 10-15 3 10 40 1 x 106
-80MCK-CAT 13 5-10 1 <2 <2 <2
14 2-5 3 <2 <2 <2
E1-117MCK-CAT 15 1 5 ' <2 6
16 2-5 5 <2 <2 60
17 1 3 <2 3 x 102 8 x 104
18 1-3 6 6 30 1 x 105
19 15-20 7 3 2 x103 1x103 3 x105+1x105
20" 10-15 1 30 6 x 102 2 x 106
21 3-5 3 60 8 x 102 2 x 106
22 10-15 3 2 x 102 2x104 6 x16
E2-776MCK-CAT 23 2-5 4 20 8 3 x 105
24 2-5 2 60 60 2 x 106
25 5-10 2 1 x 103 3 x 102 6 x 106
E2-80MCK-CAT 26" 0.5-2 1 <2 <2 25
27d 2-5 1 <2 <2 30
28d 2-5 1 <2 <2 8 x 103
"See legend to Fig. 1 for description of transgenes.6 A unit of CAT activity is defined as the amount sufficient to acetylate 1 imol of chloramphenicol per min (37). Standard deviations are given for data averaged
from seven or more mice (see Materials and Methods).
Superficial gluteus muscle.
"Founder mice were sacrificed for analysis and thus may have been mosaic. Data reported are from tissues of the founders. The gene copy number given is
a minimum measurement.
'-, Not determined.
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from 1 to 20; estimates for each line are given in Tables 1 and
2.
Expression of -3300MCK-CAT in transgenic mice. The
largest segment of MCK tested was 3,300 bp of 5' flanking
sequence, which included the site of transcription initiation
and 7 nt of 5' MCK untranslated leader fusedjo a CAT gene
cassette (Fig. 1). In multiple independent transgenic lines,
the -3300MCK-CAT gene was expressed in a pattern re-
flecting that observed for endogenous MCK. The level of
transgene expression was measured by CAT enzyme activ-
ity. Although, as in most other transgene experiments (16,
17, 28, 41), the absolute transgene expression levels varied
among different transgenic lines, skeletal muscle reproduc-
ibly contained 104- to 105-fold more CAT activity than was
detected in nonmuscle tissues such as kidney, spleen, and
liver (Table 1). Cardiac muscle contained 100-fold less CAT
activity than did skeletal muscle, but the level was still 2 to
3 orders of magnitude greater than in most nonmuscle
tissues. Brain and lung contained on average 20-fold more
CAT activity than did other nonmuscle tissues. A compari-
son of CAT and endogenous MCK RNA levels indicated that
the CAT activity measured in -3300MCK-CAT transgenic
mice was a reasonably accurate reflection of differences in
endogenous MCK gene expression among tissues (Johnson,
Ph.D. thesis). These experiments also indicated that the
correct transcription initiation site was used in the MCK-
CAT transgenes.
Multiple cis-acting MCK sequences contribute to the tran-
scriptional specificity of MCK-CAT fusion genes in transgenic
mice. To test for striated muscle-specific regulatory elements
within the 3,300-nt MCK 5' sequence, expression from three
MCK-CAT genes containing smaller 5' regions was ana-
lyzed. These had been characterized previously by transient
transfection studies, using myogenic cell lines that express
muscle-specific genes when switched to growth factor-de-
pleted media (20; J. E. Johnson, C. L. Gartside, J. B.
Jaynes, and S. D. Hauschka, Dev. Biol., in press). In
transgenic mice, the deletions to nt -1256, -723, and -80
resulted in progressive reductions in the level of CAT
expression (Fig. 2 and Table 2). The apparent 10-fold or
greater difference in expression between -3300MCK-CAT
and -1256MCK-CAT was not predicted from cell culture
studies, since this deletion had no effect on the level of
expression in differentiated skeletal muscle cell cultures.
The transgene data suggested the existence of positive
cis-acting elements in the MCK 5' sequence from -3300 to
-1256. The further decrease in skeletal muscle expression
with deletion to nt -723 was anticipated, since these trans-
genes, with the exception of line 12, lack the 5' enhancer
element. In mice containing either the -1256MCK-CAT or
the -723MCK-CAT construct, expression in nonmuscle
tissues such as kidney also decreased 10- to 100-fold (Table
2). Thus, the same 104- to 105-fold-greater relative expres-
sion in skeletal muscle versus kidney persisted in the trun-
cated MCK genes, in contrast to the lack of expression in
any tissue of the two lines of transgenic mice containing the
-80MCK-CAT fusion gene (Table 2).
Since the -3300MCK-CAT gene was expressed at 30- to
200-times-higher levels in skeletal than in cardiac muscle, it
was of particular interest to determine the behavior of the
truncated MCK sequences in cardiac tissue. When
-3300MCK-CAT was deleted to either -1256 or -723, the
mean ratio of skeletal to cardiac muscle expression in-
creased by another 100-fold. Although the expression level
in skeletal muscle also decreased when the region from















-3300 -1256 -723 -80 El-117 E2-776 E2-80
FIG. 2. CAT activity in skeletal (A) and cardiac (B) muscle from
MCK-CAT transgenic mice (Table 2). The mouse lines are in
consecutive order, beginning with line 1 in each panel. CAT activity
is expressed in log units.
muscle expression was greater. Relative to its expression
level in kidney, -723MCK-CAT appeared to have minimal,
if any, activity in cardiac muscle.
Activation of MCK-CAT fusion genes in muscle by two
MCK enhancer elements. Two MCK sequence elements have
been identified as skeletal muscle-specific enhancers in cell
culture experiments (J. B. Jaynes, Ph.D. thesis, University
of Washington, Seattle, 1987; 20, 39). These elements elicit
differential effects in skeletal and cardiac muscle of trans-
genic mice. The 5' enhancer element, El, which is normally
located between nt -1256 and -1049, was fused directly to
a basal MCK promoter at position -117. (In cell culture
transfection studies, the 117-nt MCK 5' sequence exhibits
basal-level expression similar to that of -80MCK-CAT and
has no skeletal muscle specificity; J. E. Johnson, unpub-
lished results.) The average expression levels of CAT activ-
ity in both skeletal and cardiac muscle of E1-117MCK-CAT
lines were similar to levels observed for the entire
-1256MCK-CAT gene (Fig. 2 and Table 2). Enhancement
from the El element was clearly tissue specific. In
E1-117MCK-CAT mice, CAT activity in skeletal muscle
was 104 to 105 times greater than in kidney, a ratio similar to
that found for mice carrying 3,300, 1,256, and 723 nt ofMCK
5' sequence. CAT activity in cardiac muscle was more
variable but was still 5- to 103-fold greater than in kidney.
This variability may have resulted from greater sensitivity of
the regulatory element in cardiac tissue to chromosomal
position effects. It is clear, however, that the 5' enhancer
element, in combination with the 117-nt 5' MCK flanking
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region, contains regulatory information for expression in
skeletal and cardiac muscle as well as very low level
expression in kidney.
The 900-nt intron 1 enhancer element, E2, had a large
quantitative effect on transcription when positioned 5' to the
-776 MCK sequence (Fig. 2 and Table 2). All transgenic
lines containing E2-776MCK-CAT expressed CAT activity
in skeletal muscle at high levels (0.3 x 106 to 6 x 106 p.U/mg
of protein) that were about 104 times greater than in kidney.
When the E2 enhancer was not present on the transgene (as
in the -723MCK-CAT construct), only one of five lines
expressed such high CAT activity in skeletal muscle (com-
pare E2-776MCK-CAT with -723MCK-CAT in Fig. 2 and
Table 2). These data raised the possibility that all of the
skeletal muscle specificity observed for the E2-containing
construct resides in the -776 segment, with E2 acting only
to enhance that expression. Alternatively, E2 might contain
muscle specificity of its own that could not be detected
above that provided by the -776 element in the
E2-776MCK-CAT construct. To distinguish between these
possibilities, an E2 construct (E2-80MCK-CAT) containing
a basal MCK promoter element with no skeletal muscle
specificity was tested. In three independent transgenic
founder mice, E2-80MCK-CAT expression was detected
only in skeletal muscle (Table 2). These results are consis-
tent with a tissue-specific role for E2 in skeletal muscle
expression of MCK. A less plausible but formal possibility is
that the 160 nt of vector sequence that is unique to the
E2-776MCK-CAT and E2-80MCK-CAT transgenes is re-
sponsible for activating expression. Strong positive tissue-
specific effects due to vector sequence are, however, un-
precedented.
The E2 transgene data are consistent with the possibility
that the intron 1 enhancer is nonfunctional in cardiac muscle.
In contrast to the expression of E2-776MCK-CAT in skel-
etal muscle, expression in cardiac muscle was no greater
than the low-level expression detected in kidney (Table 2).
In addition, no expression of E2 in conjunction with a basal
MCK promoter (E2-80MCK-CAT) was detected in cardiac
muscle. These results suggest that E2 may play no role in
MCK expression in cardiac muscle, but further dilineation of
E2 control elements is necessary before this conclusion
becomes firm.
DISCUSSION
Tissue specificity of MCK gene expression. A 3,300-nt
segment ofMCK 5' sequence is sufficient to direct high-level
expression in a tissue-specific pattern in multiple transgenic
lines. -3300MCK-CAT activity in skeletal muscle was 104 to
105 greater than in nonmuscle tissues such as kidney, liver,
and spleen. Expression in cardiac muscle was also high,
albeit 10- to 100-fold less than in skeletal muscle. Although
-3300MCK-CAT was expressed at the highest levels in
skeletal and cardiac muscle, we also found moderately high
levels of CAT activity in brain and lung. This result is
consistent with the low levels of endogenous MCK RNA
that have been detected in mouse brain and lung (Johnson,
Ph.D. thesis) and also with the low levels of the muscle
isoform of creatine kinase reported in brains from adult rats
(11) and in lungs from adult humans (12, 21). Low levels of
MCK enzyme activity have also been reported in macro-
phages, which are present in lung tissue (23), and these cells
may be responsible for some or all of the MCK RNA
detected in lung tissue as well as for the low levels of CAT
enzyme activity detected in tissues such as testes, uterus,
kidney, liver, spleen, and blood. In summary, the four
tissues expressing the -3300MCK-CAT transgene at the
highest levels are those that are known to express the
endogenous MCK gene.
Two other murine muscle-specific genes, rat skeletal ox-
actin and myosin light chain 2, have also been tested in
transgenic mice (10, 35, 36). Transgenes containing two-
thirds of the rat skeletal muscle actin gene, including 730 bp
of 5' flanking sequence fused to the 3' end of human
embryonic globin, were expressed "exclusively" in skeletal
and cardiac muscle. Transgenes containing myosin light
chain 2 were expressed only in skeletal muscle. The lower
sensitivity of RNA transcript detection relative to CAT
enzyme activity may have precluded detection of low-level
transgene expression in other tissues.
MCK transcription in skeletal muscle. Deletion of MCK
from -3300 to -1256 and to -723 resulted in 10- and
100-fold decreases in the average level of CAT expression in
skeletal muscle (Table 2 and Fig. 2). Even though the levels
of expression were dramatically reduced by these deletions,
muscle specificity remained high (104-times-greater activity
in skeletal muscle than in kidney) (Table 2). These data are
consistent with a model for MCK regulation in which the
sequences that regulate muscle specificity reside in the
723-nt segment, with upstream elements providing only
quantitative amplification. However, data from mouse lines
containing the E1-117MCK-CAT transgene indicate that El
also confers muscle specificity (Table 2). E2, the intron
enhancer, also increased MCK transcription in skeletal
muscle (Table 2).
It is interesting to note that while deletion of sequences
between -3300 and -1256 had a significant quantitative
effect in transgenic animals, the same deletion had no
detectable effect in transfected myogenic cells (20; Johnson
et al., in press). This may reflect an important difference in
the sensitivity of the two systems to regulatory elements
between -3300 and -1256. Alternatively, this deletion may
render important internal sequences such as the El enhancer
more sensitive to negative position effects in transgenic
mice.
MCK transcription in cardiac muscle. Introduction of
MCK-CAT genes into the mouse germ line permitted an
analysis of MCK regulatory elements that affect expression
in cardiac muscle. Studies of MCK enzyme activity indicate
that adult rodent cardiac muscle contains 10 to 15 times less
MCK than does skeletal muscle (11, 15, 40). A comparable
ratio of skeletal to cardiac muscle expression was ap-
proached in transgenic experiments only when the full 3,300
nt of MCK 5' sequence was present. When sequences
between -3300 and -1256 were deleted, the mean ratio of
skeletal to cardiac expression appeared to increase about
200-fold. A simple explanation for this observation is that
one or more distinct cardiac regulatory elements reside
between nt -3300 and -1256. Consistent with this possibil-
ity, distinct skeletal- versus cardiac-specific regulatory se-
quences in the chicken troponin T gene have been identified
by using primary cell cultures (24). Although there are other,
more complex explanations for the relative loss of cardiac
expression, this segment of MCK DNA can now be tested
directly for the ability to act on a basal promoter to specify
cardiac expression.
Although both MCK enhancers increase transcription in
skeletal muscle, the 5' enhancer but not the intron enhancer
also increases transcription in cardiac muscle. The 5' en-
hancer is similar to the full -3,300-nt sequence in its ability
to direct MCK-CAT expression in cardiac muscle relative to
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other tissues (Table 2, see E1-117MCK-CAT). In contrast,
the intron enhancer does not activate expression in cardiac
muscle over the expression seen in kidney (Table 2, see
E2-776MCK-CAT and E2-80MCK-CAT). A possible am-
biguity here is that two of the E2-80MCK-CAT mice
expressed CAT at such low levels in skeletal muscle that 10-
to 100-lower levels of expression in cardiac muscle might not
have been detectable. Nevertheless, these results, suggest-
ing differences in function of the El and E2 enhancers, are
reminiscent of those reported for a-fetoprotein. In a tran-
sient-expression system in hepatoma cells, the three enhanc-
ers of o-fetoprotein had essentially equivalent and nonaddi-
tive activities, but when tested in transgenic mice, the
enhancers had different biological effects (13, 16). The data
for o-fetoprotein and MCK suggest that these are examples
of genes in which multiple, distinct enhancer elements are
responsible for modulation of transcription in a tissue-
specific manner during different stages of development and
under diverse physiological conditions.
Implications for muscle-specific gene expression. In light of
recent data on muscle-specific gene regulation, it is of
particular interest that the 207-bp 5' enhancer appears to
function in both skeletal and cardiac muscle. A muscle-
specific binding factor (MEF1), which binds to both the El
and E2 enhancers, is identical or closely related to MyoDl,
a putative myogenic determination factor (5, 9; Buskin et al.,
J. Cell Biol. 107:98a, 1988; Lassar et al., submitted). When
the MEF1 binding sequence is mutated, El loses its ability to
enhance MCK expression in differentiating skeletal myo-
blasts in culture (5). MyoDI, however, is present only in
skeletal muscle, not cardiac muscle (9). These data suggest
that in cardiac muscle, the MEF1 sequence of El is recog-
nized by a MyoDl-related protein or, alternatively, that El
contains another distinct sequence which functions specifi-
cally in cardiac muscle. Studies with transgenic mice con-
taining El mutations will distinguish between these two
possibilities.
This study has focused on identifying sequence elements
in the mouse MCK gene that are quantitatively important in
skeletal and cardiac muscle-specific expression in adult
animals. It will now be interesting to evaluate the behavior of
these constructs at earlier points in development, when the
distribution of brain and muscle creatine kinase isoforms is
significantly different from that in adult animals (11, 15, 43).
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